United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - glycopyrronium bromide - oral tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - glycopyrronium bromide - oral tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - glycopyrronium bromide - oral tablet - 1mg

Ireland - English - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - glycopyrronium bromide - solution for injection - 200 microgram(s)/millilitre - synthetic anticholinergics, quaternary ammonium compounds; glycopyrronium bromide

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - glycopyrronium bromide - oral tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

p.i.e. pharma ltd - glycopyrronium bromide - oral tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - glycopyrronium bromide - oral tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - glycopyrronium bromide - oral tablet - 1mg

Ireland - English - HPRA (Health Products Regulatory Authority)

mercurypharm ltd - glycopyrronium bromide - solution for injection - 200 microgram(s)/millilitre - synthetic anticholinergics, quaternary ammonium compounds; glycopyrronium bromide

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram); mometasone furoate, quantity: 80 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.